Persistent non-dental orofacial pain is common yet poorly characterised, and its pathophysiology remains largely unknown. Two clinically similar entities are distinguished: post-traumatic trigeminal neuropathic pain (PTNP), in which peripheral nerve damage is demonstrable, and persistent idiopathic facial pain (PIFP), in which peripheral findings are typically absent - pointing to an altered central processing of trigeminal nociceptive input. This monocentric study characterises the peripheral and central mechanisms of PIFP by comparing PIFP patients with age- and sex-matched healthy controls using a combination of non-invasive peripheral and central approaches.
The study comprises two work packages. The peripheral work package uses quantitative sensory testing (standardised DFNS protocol) to test the hypothesis that PIFP patients retain an intact peripheral nervous system. The central work package uses functional MRI with standardised trigemino-nociceptive stimulation to characterise brainstem network dynamics, testing the hypothesis that PIFP patients exhibit a central trigeminal processing disturbance at the brainstem level. In PIFP patients, the functional MRI is repeated before and after a local-anaesthetic nerve block in the pain area, additionally distinguishing patients whose pain is completely abolished by the block from those with persistent pain despite it. The overarching aim is to characterise the pathophysiological basis of PIFP and thereby advance the mechanistic understanding of persistent orofacial pain.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Healthy controls: written informed consent.
* PIFP cohort: written informed consent, and a diagnosis of PIFP according to the ICHD-3 and ICOP diagnostic criteria.
Exclusion Criteria:
* Contraindication to MR scanning
* Anxiety disorders, including claustrophobia
* Other somatic diseases, including other pain disorders
* Other primary headache disorders and medication-overuse headache
* Skin lesion , infection, or scarring at the stimulation sites preventing safe electrode placement
* Healthy volunteers: any history of persistent pain or primary headache, including in first-degree relatives
* History of psychiatric disease and/or addiction
* Pregnancy or lactation
* Any regular medication; in PIFP patients, occasional acute analgesic use (NSAID, fewer than 8 days per month) is permitted
* Use of acute analgesic within 24 hours before the experiment
Primary outcome measure(s)
Difference in brain functional neuroimaging response to standardized trigemino-nociceptive stimulation between PIFP patients HC — Baseline (MRI session before local anesthesia) BOLD signal change (contrast estimates, arbitrary units) during standardized trigemino-nociceptive stimulation versus baseline, compared between PIFP patients and HC in a priori defined regions of interest and at whole-brain level.
Difference in brain activation before versus after the local-anesthetic nerve block, and between complete responders and non-responders — Pre-block MRI at baseline and post-block MRI, both on the same day 1 BOLD signal change (contrast estimates, arbitrary units) during standardized trigemino-nociceptive stimulation, compared within participants before versus after the local-anesthetic nerve block, and between participants whose pain is completely abolished by the block and those with persistent pain despite the block
Trial sites (1)
Facility
City
Region
Status
University Medical Center Hamburg-Eppendorf
Hamburg
Germany
More Universitätsklinikum Hamburg-Eppendorf trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.